News

Novel FGFR2 Inhibitor Shows Promise in Patients With Cholangiocarcinoma and an FGFR2-Fusion or Rearrangement

10/20/2022

Allison Casey

According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.

According to a phase 1/2 study,...

10/20/2022

Oncology

News

FDA Approves Futibatinib for Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusions or Rearrangements

10/03/2022

Allison Casey

On September 30, 2022, the US FDA granted accelerated approval to futibatinib, 20 mg orally daily, for patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.

On September 30, 2022, the US...

10/03/2022

Oncology

News

Derazantinib Showed Clinical Benefit as a Second-Line Treatment for Patients With Intrahepatic Cholangiocarcinoma and EGFR2 Aberrations

09/30/2022

Allison Casey

Results from a phase 2 trial showed that derazantinib as a second-line treatment resulted in meaningful clinical benefit for patients with intrahepatic cholangiocarcinoma and EGFR2 aberrations.

Results from a phase 2 trial...

09/30/2022

Oncology

News

Nivolumab Plus Gemcitabine and S-1 Demonstrates Potential in Advanced Biliary Tract Cancer

09/28/2022

Allison Casey

Results from a phase 2 trial show that modified gemcitabine and S-1 plus nivolumab is a safe and promising regimen for patients with advanced biliary tract cancer, with impaired function of chromatin remodeling genes as a potential surrogate...

Results from a phase 2 trial...

09/28/2022

Oncology

News

Nivolumab Added to Chemotherapy or Ipilimumab Offers No Survival Benefit in Advanced Biliary Tract Cancer

08/31/2022

Allison Casey

Findings from a phase 2 trial suggest adding nivolumab to either chemotherapy or ipilimumab provides no PFS benefit in the first-line treatment of patients with advanced biliary tract cancer.

Findings from a phase 2 trial...

08/31/2022

Oncology

News

Second-Line Sintilimab Plus Lenvantinib Demonstrates Efficacy, Safety in Intrahepatic Cholangiocarcinoma

08/31/2022

Allison Casey

In the second-line treatment setting, sintilimab combined with lenvatinib demonstrated promising efficacy and tolerability among patients with advanced intrahepatic cholangiocarcinoma, according to a multicenter observational study.

In the second-line treatment...

08/31/2022

Oncology

News

Immune Checkpoint Inhibitor Monotherapy Demonstrates Antitumor Activity in Advanced Biliary Tract Cancer

08/10/2022

Allison Casey

Study findings show immune checkpoint inhibitors are well-tolerated and demonstrate antitumor activity in patients with biliary tract cancers, especially those with high tumor mutational burden.

Study findings show immune...

08/10/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Conference Coverage

Durvalumab Added to Gemcitabine and Cisplatin Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

06/30/2022

Allison Casey

First-line treatment with durvalumab plus gemcitabine and cisplatin was associated with improved efficacy outcomes among patients with biliary tract cancer irrespective of the primary tumor location, according to results from the phase 3...

First-line treatment with...

06/30/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology